Publication:

p53 Modulates the Fate of Cardiac Progenitor Cells Ex Vivo and in the Diabetic Heart In Vivo

Loading...
Thumbnail Image

Open/View Files

Date

2017

Journal Title

Journal ISSN

Volume Title

Publisher

Elsevier
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Kannappan, R., A. Matsuda, J. Ferreira-Martins, E. Zhang, G. Palano, A. Czarna, M. C. Cabral-Da-Silva, et al. 2017. “p53 Modulates the Fate of Cardiac Progenitor Cells Ex Vivo and in the Diabetic Heart In Vivo.” EBioMedicine 16 (1): 224-237. doi:10.1016/j.ebiom.2017.01.028. http://dx.doi.org/10.1016/j.ebiom.2017.01.028.

Abstract

p53 is an important modulator of stem cell fate, but its role in cardiac progenitor cells (CPCs) is unknown. Here, we tested the effects of a single extra-copy of p53 on the function of CPCs in the presence of oxidative stress mediated by doxorubicin in vitro and type-1 diabetes in vivo. CPCs were obtained from super-p53 transgenic mice (p53-tg), in which the additional allele is regulated in a manner similar to the endogenous protein. Old CPCs with increased p53 dosage showed a superior ability to sustain oxidative stress, repair DNA damage and restore cell division. With doxorubicin, a larger fraction of CPCs carrying an extra-copy of the p53 allele recruited γH2A.X reestablishing DNA integrity. Enhanced p53 expression resulted in a superior tolerance to oxidative stress in vivo by providing CPCs with defense mechanisms necessary to survive in the milieu of the diabetic heart; they engrafted in regions of tissue injury and in three days acquired the cardiomyocyte phenotype. The biological advantage provided by the increased dosage of p53 in CPCs suggests that this genetic strategy may be translated to humans to increase cellular engraftment and growth, critical determinants of successful cell therapy for the failing heart.

Description

Research Data

Keywords

CPC, cardiac progenitor cell, DDR, DNA damage response, WT, wild type, LV, left ventricle, p53-tg, super-p53 transgenic mouse, Aogen, angiotensinogen, Ang II, angiotensin II, AT1R, Ang II type-1 receptor, PDT, population doubling time, ROS, reactive oxygen species, Doxo, doxorubicin, Stem cell engraftment, Diabetes, DNA repair, Stem cell fate

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Related Stories